Inflammatory Regulation Effect of NAC on COVID-19 Treatment
NCT ID: NCT04455243
Last Updated: 2020-07-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
1180 participants
INTERVENTIONAL
2020-08-01
2021-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Exploratory Efficacy of N-Acetylcysteine in Patients With History of COVID-19
NCT05736887
A Study of N-acetylcysteine in Patients With COVID-19 Infection
NCT04374461
Clinical Trial With N-acetylcysteine and Bromhexine for COVID-19
NCT04928495
Administration of Anti-SARS-CoV-2 Convalescent Plasma in Hospitalized, Non-ICU Patients With COVID-19
NCT04467151
A Clinical Trial for Azvudine in the Treatment of Novel Coronavirus Pneumonia (COVID-19）
NCT04425772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
N-Acetyl cysteine
150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
Control group
Placebo
Matching placebo administered in the same schedule and volume as NAC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
N-Acetyl cysteine
150 mg/kg every 12 hours for 14 days (oral/IV) Diluted in 200 ml diluent (D5%, NS)
Placebo
Matching placebo administered in the same schedule and volume as NAC
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admitted to the hospital With confirmed COVID-19 by RT-PCR test
* On oxygen supplement
Exclusion Criteria
* Known NAC allergy
* In the opinion of the treating team, progression of death is imminent and inevitable within the next 24 hour, irrespective of provision treatment
* All patients enrolled in any other investigational drug studies in COVID-19.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr. Tariq Alhawassi
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dr. Tariq Alhawassi
Chairman of Clinical Trial Support Unit
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
E-20-4934
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.